Knight Therapeutics Inc.
GUD.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 101.54M | 106.74M | 95.48M | 88.25M | 77.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 101.54M | 106.74M | 95.48M | 88.25M | 77.59M |
| Cost of Revenue | 52.52M | 57.05M | 49.05M | 47.73M | 45.19M |
| Gross Profit | 49.02M | 49.70M | 46.43M | 40.52M | 32.40M |
| SG&A Expenses | 25.80M | 24.77M | 25.43M | 22.52M | 20.29M |
| Depreciation & Amortization | 9.48M | 10.55M | 9.92M | 11.21M | 7.76M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.23M | 99.13M | 91.02M | 87.78M | 77.78M |
| Operating Income | 6.31M | 7.61M | 4.45M | 469.00K | -180.70K |
| Income Before Tax | -1.48M | 10.20M | 8.05M | -1.39M | -11.28M |
| Income Tax Expenses | 885.80K | 728.40K | 1.70M | 1.36M | -2.16M |
| Earnings from Continuing Operations | -2.37M | 9.47M | 6.35M | -2.75M | -9.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.37M | 9.47M | 6.35M | -2.75M | -9.12M |
| EBIT | 6.31M | 7.61M | 4.45M | 469.00K | -180.70K |
| EBITDA | 16.88M | 19.25M | 11.81M | 13.37M | 8.59M |
| EPS Basic | -0.02 | 0.10 | 0.06 | -0.03 | -0.09 |
| Normalized Basic EPS | 0.03 | 0.07 | 0.01 | 0.01 | -0.03 |
| EPS Diluted | -0.02 | 0.09 | 0.06 | -0.03 | -0.09 |
| Normalized Diluted EPS | 0.03 | 0.07 | 0.01 | 0.01 | -0.03 |
| Average Basic Shares Outstanding | 98.20M | 98.46M | 99.34M | 99.66M | 99.63M |
| Average Diluted Shares Outstanding | 98.20M | 98.93M | 99.86M | 99.66M | 99.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |